Artisan Partners Limited Partnership Acquires New Stake in Cencora, Inc. $COR

Artisan Partners Limited Partnership bought a new position in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 1,373,648 shares of the company’s stock, valued at approximately $411,888,000. Artisan Partners Limited Partnership owned approximately 0.71% of Cencora at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of COR. Voleon Capital Management LP purchased a new position in Cencora in the first quarter valued at $3,111,000. Focus Partners Wealth raised its position in Cencora by 25.8% in the 1st quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after purchasing an additional 1,171 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after buying an additional 232,539 shares during the period. Fiduciary Alliance LLC acquired a new position in shares of Cencora during the second quarter worth about $262,000. Finally, Martin Capital Partners LLC grew its position in shares of Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after buying an additional 2,544 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the sale, the chief executive officer owned 65,746 shares in the company, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 46,640 shares of company stock valued at $14,099,338. 10.80% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on COR shares. UBS Group raised their target price on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a report on Friday, November 7th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Wells Fargo & Company lifted their price objective on shares of Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Evercore ISI set a $400.00 target price on Cencora and gave the company an “outperform” rating in a report on Thursday, November 6th. Finally, TD Cowen raised their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average target price of $371.09.

Cencora Stock Performance

Shares of COR stock opened at $360.79 on Thursday. The stock’s 50-day moving average is $325.26 and its two-hundred day moving average is $303.65. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. Cencora, Inc. has a 1 year low of $223.92 and a 1 year high of $369.00. The firm has a market cap of $69.95 billion, a price-to-earnings ratio of 37.12, a PEG ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion during the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The business’s revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be given a $0.60 dividend. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is currently 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.